

The use of alpha-lipoic acid supplementation in diabetes: The available evidence

Aamir Jalal Al-Mosawi*

Advisor and expert trainer, Baghdad Medical City and the National Training and Development Center, Iraqi Ministry of Health, Baghdad, Iraq

***Corresponding Author:** Aamir Jalal Al-Mosawi. Advisor and expert trainer, Baghdad Medical City and the National Training and Development Center, Iraqi Ministry of Health, Baghdad, Iraq.

Received: 10 December 2022; **Accepted:** 20 December 2022; **Published:** 27 December 2022.

Citation: Aamir Jalal Al-Mosawi (2022). The use of alpha-lipoic acid supplementation in diabetes: The available evidence. Journal of Clinical Trials and Bioavailability Research (JCTBR).1(1). DOI: 10.58489/JCTBR.003. DOI: 10.58489/2836-5836/003.

Copyright: © 2022 Aamir Jalal Al-Mosawi, this is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Dietary health supplements have been increasingly used in the treatment and prevention of chronic disorders. During the previous years, lipoic acid has been reported to have a beneficial effect on diabetes and some of its complications. The aim of this paper is to review the evidence provided by lipoic acid research findings relevant to its use in diabetes. Since, the 1950s, there has been accumulating experimental evidence showing that lipoic acid, a naturally occurring substance, has a protective effect against the development of diabetes and its complications especially neuropathy. The beneficial use of oral lipoic acid in diabetic neuropathy has been reported mostly from Germany as early as the 1960s. There is convincing research evidence suggesting that lipoic acid has a beneficial effects in diabetes, and is particularly useful in the prevention and treatment of diabetic neuropathy. The beneficial effects of lipoic acid in diabetes and diabetic neuropathy are attributed to increasing insulin sensitivity, reduction of hyperglycemia-induced oxidative stress, and lipid peroxidation. Lipoic acid can possibly help in preventing diabetes in susceptible individuals, and the current expert opinion suggests that lipoic acid can be used in patients with patients with impaired glucose tolerance.

Keywords: Lipoic acid, diabetes, research findings, expert opinion.

Introduction

During the 1950s, experimental studies showed that lipoic acid; a naturally occurring substance can prevent the development of alloxan diabetes in rats [1].

The use of oral lipoic acid in diabetic neuropathy has been reported as early as the 1960s [2].

Klein (1975) reported the treatment of 100 patients who had diabetic neuropathy with oral alpha-lipoic acid. Treatment was considered successful in 23 patients of 29 patients who received 50 mg twice daily, and in 51 of 60 patients who received 100 mg twice daily [3].

Faust et al (1994) from Germany reported an experimental study on non-obese diabetic mice with type I diabetes which showed that lipoic acid had a protective effect against the development of

cyclophosphamide-induced diabetes. The anti-diabetic effect of lipoic acid was associated with partial inhibition of islet inflammation. The anti-inflammatory effect of lipoic acid was attributed to scavenging oxygen radicals and to inhibiting nitric oxide generation [4].

Strödter et al (1995) from Germany reported an experimental study on streptozotocin induced type 1 diabetes and cardiomyopathy in rats which showed that lipoic acid has beneficial anti-diabetic effects on cardiac metabolism and has the potential of correcting metabolic and hemodynamic abnormalities of diabetes in the heart. The suggested mechanisms of action include [5]:

1-Increasing glucose uptake.

2-Improving utilization of endogenous glycogen in the diabetic heart through increasing glycogen breakdown.

Clinical Trails and Bioavailability Research

3-Increasing glucose oxidation.

Jacob et al (1995) from Germany reported a study which included thirteen patients with type II diabetes. Seven patients received lipoic acid 1g in 500 ml NaCl, and six patients received 500 ml NaCl without lipoic acid. Parenteral lipoic acid was associated with a considerable elevation of insulin-stimulated disposal of glucose [6].

Nagamatsu et al (1995) from the USA reported an experimental study on streptozotocin induced diabetes which showed that the nerve blood flow in the diabetic animals was reduced by 50%, and it returned to normal after one month of treatment with lipoic acid 100 mg per kilogram. This beneficial effect was associated with evidence of reduction of oxidative stress [7].

Ziegler et al (1995) from Germany reported a 3-week double-blind placebo-controlled study which included 328 diabetic patients (non-insulin-dependent) from several centers who had symptomatic peripheral neuropathy. The patients were treated with intravenous infusion of alpha-lipoic acid using or placebo. The study showed that intravenous alpha-lipoic acid in a dose of 600 mg daily for three weeks was associated with significant reduction of the symptoms of diabetic peripheral neuropathy, and was not associated with important adverse reactions [8].

Khamaisi et al (1997) reported an experimental study on rats with streptozotocin induced diabetes which showed that daily treatment with lipoic acid can decrease blood glucose level in diabetic rats by augmenting gastrocnemius muscle crude membrane protein content and by improving muscle glucose utilization [9].

Ziegler et al (1999) reviewed the evidence available from clinical trials in Germany using alpha-lipoic acid in the treatment of diabetic polyneuropathy. They found that Treatment with lipoic acid 600 mg intravenously for three weeks improves the main symptoms of diabetic polyneuropathy. Oral lipoic acid for 4-7 months can improve neuropathic deficits and cardiac autonomic neuropathy. Two years treatment can lead to long-term improvements in motor and sensory nerve conduction in the lower limbs. Ziegler et al emphasized that treatment with lipoic acid is very safe [10].

Khamaisi (1999) emphasized that lipoic acid is an anti-oxidant that has a beneficial effect in diabetes that is attributed to enhancing utilization of peripheral glucose. They reported an experimental study which included non-diabetic and diabetic rats having streptozotocin-induced diabetes. The study showed

that short-term intake of lipoic acid at high dosage to non-diabetic rats can inhibit gluconeogenesis through interfering with fatty acid oxidation in the liver [11]. This finding suggests that lipoic acid can possibly help in preventing diabetes in susceptible individuals.

Jacob et al (1999) from Germany reported a study which included 74 diabetic patients (Type-2). Nineteen patients received 600 mg lipoic acid once daily, eighteen patients received 600 mg lipoic acid twice daily, eighteen patients received 600 mg lipoic acid three times daily, and nineteen patients received placebo. All patients who received lipoic acid experienced considerably different changes in insulin-stimulated glucose disposal and improvement insulin sensitivity after one month of treatment [12].

Gleiter et al (1999) from Germany reported a study which included 14 male and 10 female healthy volunteers and showed that lipoic acid in a dose of 600 mg has no interaction with glibenclamide and acarbose, a commonly used oral anti-diabetic agents [13].

Cakatay et al (2000) from Turkey reported an experimental placebo-controlled study on male Wistar rats which showed that the increased lipid hydro-peroxide which occurs in association with streptozotocin diabetes is significantly reduced by alpha-lipoic acid suggesting that alpha-lipoic can reduce oxidative stress [14].

Androne et al (2000) emphasized that diabetes is accompanied by oxidative stress and the

associated lipid peroxidation of nerve membranes contributes to the development of ischemia and hypoxia of peripheral nerve which lead to neuropathy. They reported a study which included 10 diabetic patients with neuropathy and twelve healthy individuals as controls. The study showed that treatment with lipoic acid for 70 days was associated with lowering of lipid peroxide an index of lipid peroxidation [15].

The experimental work of Obrosova and colleagues on rats with streptozotocin-induced diabetes suggested that excessive 4-hydroxyalkenals is an early indicator of retinal oxidative stress in the diabetes. Lipid peroxidation increases in the diabetic retina despite the availability of reduced glutathione, and alpha-lipoic acid reduce lipid peroxidation [16].

Strokov et al (2000) from Moscow emphasized that alpha lipoic acid is a powerful antioxidant that is effective for the prevention and treatment of diabetic neuropathy. They found that plasma level of nitrites and nitrates in patients with insulin-dependent

diabetes and polyneuropathy was about 2-fold less than the normal. However, Alpha-lipoic acid treatment was associated with completely normalization of plasma level of nitrites and nitrates. They also reported that most patients with insulin-dependent diabetes and polyneuropathy had also lower level of stress proteins (HSP72). Alpha-lipoic acid treatment was also associated normalization of stress proteins (HSP72) level. Therefore, Stokov et al suggested that activation of nitric oxide and stress proteins HSP protective systems contributes to the therapeutic effect of alpha-lipoic acid in type 1 diabetes mellitus associated with polyneuropathy [17].

The experimental work of Melhem and colleagues (2001) on rats with streptozotocin diabetes suggested that lipoic acid supplementation could possibly help in the prevention early glomerular injury through increasing glutathione in the renal cortex [18].

Tankova and colleagues (2004) from Bulgaria reported a controlled study which included

46 diabetic patients (Type 1) who various forms of autonomic neuropathy. They were treated with 600 mg of intravenous alpha-lipoic acid given daily for ten days, followed by oral lipoic, 600 mg/day for fifty days. 29 diabetic patients (Type 1) with autonomic diabetic neuropathy were included in the study as controls.

Treatment was associated with a considerable improvement in cardiovascular autonomic neuropathy with a beneficial effect on the change of systolic blood pressure at the lying-to-standing test. Improvement in diabetic enteropathy was observed in six patients. Six patients reported improvement in dizziness and instability upon standing. Four patients reported improvement in neuropathic edema of the lower limbs. Four patients reported improvement in erectile dysfunction.

Therefore, lipoic acid was considered to be useful in the treatment of various forms of autonomic diabetic neuropathy [19].

Hahm and colleagues (2004) from South Korea reported a study which included 61 diabetic patients with polyneuropathy associated with pain, burning sensation, paresthesia, and numbness. The patients were treated with oral lipoic acid 600 mg once daily for two months. 38 patients completed 2 months of the study. The overall efficacy was estimated at about 76%, and treatment was not associated with occurrence of serious side effects [20].

Liu et al (2007) from China reported the treatment of fifty diabetic patients (Type 2) who had peripheral neuropathy with lipoic acid 600 mg given in 250 normal salines once daily for two weeks. The findings

were compared with a placebo group which included 43 diabetic patients (Type 2) who had peripheral neuropathy and received radix salviae infusion. Lipoic acid treatment was associated with an improvement rate of 90% which was considerably higher than the placebo group [21].

Xiang et al (2008) from China reported a controlled study which included 42 patients with impaired glucose tolerance and 26 healthy controls group. 21 one patents received 300 mg of alpha-lipoic acid before oral glucose tolerance test, while the remaining 21 one patents and the 26 healthy controls received 0.9% sodium chloride (250 ml) before oral glucose tolerance test.

The patients with impaired glucose tolerance had endothelial dysfunction (Lower flow-mediated endothelium-dependent arterial dilation measured by high-resolution ultrasound) in the fasting state and after a glucose challenge. Treatment with alpha lipoic acid was associated with improvement in endothelial dysfunction which is considered early warning of the development of atherosclerosis [22].

Han et al (2012) from China conducted a meta-analysis which included randomized controlled trial studying the use of α -lipoic acid in diabetic peripheral neuropathy. The meta-analysis revealed that treatment with intravenous α -lipoic acid 300-600 mg daily for 2-4 weeks was safe and associated improvement in nerve conduction velocity and neuropathic symptoms [23].

Cassanego et al (2022) conducted a systematic review and meta-analysis of randomized controlled trials which included nine studies studying the use of lipoic acid in diabetic polyneuropathy, and recommended that lipoic should be considered in the treatment of diabetic polyneuropathy [24].

Conclusion

There is convincing research evidence suggesting that lipoic acid has a beneficial effects in diabetes, and is particularly useful in the prevention and treatment of diabetic neuropathy. The beneficial effects of lipoic acid in diabetes and diabetic neuropathy are attributed to increasing insulin sensitivity, reduction of hyperglycemia-induced oxidative stress, and lipid peroxidation. Lipoic acid can possibly help in preventing diabetes in susceptible individuals, and the current expert opinion suggests that lipoic acid can be used in patients with patients with impaired glucose tolerance.

Conflict of interest

None.

References

References

1. CUTOLO, E., & REDUZZI, F. (1955). L'acido tioctico inibisce l'insorgere del diabete da allossana nel ratto [Thioctic acid inhibition of development of alloxan diabetes in rats]. *Bollettino della Societa italiana di biologia sperimentale*, 31(11-12), 1532–1533.
2. SLADKI, E., MALDYK, H., & PRUSINSKI, A. (1963). *Polski tygodnik lekarski (Warsaw, Poland : 1960)*, 18, 16–18.
3. Klein W. (1975). Die Behandlung der Neuropathia diabetica mit oralen Gaben von alpha-Liponsäure [Treatment of diabetic neuropathy with oral alpha-lipoic acid (author's transl)]. *MMW, Munchener medizinische Wochenschrift*, 117(22), 957–958.
4. Faust, A., Burkart, V., Ulrich, H., Weischer, C. H., & Kolb, H. (1994). Effect of lipoic acid on cyclophosphamide-induced diabetes and insulinitis in non-obese diabetic mice. *International journal of immunopharmacology*, 16(1), 61–66
5. Strödter D, Lehmann E, Lehmann U, Tritschler HJ, Bretzel RG, Federlin K. (1995). The influence of thioctic acid on metabolism and function of the diabetic heart. *Diabetes Res Clin Pract* Jul; 29(1):19-26.
6. Jacob, S., Henriksen, E. J., Schieman, A. L., Simon, I., Clancy, D. E., Tritschler, H. J., Jung, W. I., Augustin, H. J., & Dietze, G. J. (1995). Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. *Arzneimittel-Forschung*, 45(8), 872–874.
7. Nagamatsu, M., Nickander, K. K., Schmelzer, J. D., Raya, A., Wittrock, D. A., Tritschler, H., & Low, P. A. (1995). Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. *Diabetes care*, 18(8), 1160–1167.
8. Ziegler, D., Hanefeld, M., Ruhnau, K. J., Meissner, H. P., Lobisch, M., Schütte, K., & Gries, F. A. (1995). Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). *Diabetologia*, 38(12), 1425–1433.
9. Khamaisi, M., Potashnik, R., Tirosh, A., Demshchak, E., Rudich, A., Tritschler, H., Wessel, K., & Bashan, N. (1997). Lipoic acid reduces glycemia and increases muscle GLUT4 content in streptozotocin-diabetic rats. *Metabolism: clinical and experimental*, 46(7), 763–768.
10. Ziegler, D., Reljanovic, M., Mehnert, H., & Gries, F. A. (1999). Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association*, 107(7), 421–430.
11. Khamaisi, M., Rudich, A., Potashnik, R., Tritschler, H. J., Gutman, A., & Bashan, N. (1999). Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats. *Metabolism: clinical and experimental*, 48(4), 504–510.
12. Jacob, S., Ruus, P., Hermann, R., Tritschler, H. J., Maerker, E., Renn, W., Augustin, H. J., Dietze, G. J., & Rett, K. (1999). Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. *Free radical biology & medicine*, 27(3-4), 309–314.
13. Gleiter CH, Schreeb KH, Freudenthaler S, Thomas M, Elze M, Fieger-Büsches H, Potthast H, Schneider E, Schug BS, Blume HH, Hermann R. (1999). Lack of interaction between thioctic acid, glibenclamide and acarbose. *Br J Clin Pharmacol Dec*; 48(6):819-25.
14. Cakatay U, Telci A, Kayali R, Sivas A, Akçay T. (2000). Effect of alpha-lipoic acid supplementation on oxidative protein damage in the streptozotocin-diabetic rat. *Res Exp Med (Berl) Feb*; 199(4):243-51.
15. Androne L, Gavan NA, Veresiu IA, Orasan R. (2000). In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy *In Vivo. Mar-Apr*; 14(2):327-30.
16. Obrosova IG, Fathallah L, Greene DA. (2000). Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. *Eur J Pharmacol. Jun 9*; 398(1):139-46.
17. Stokov IA, Manukhina EB, Bakhtina LY, Malyshev IY, Zoloev GK, Kazikhanova SI, Ametov AS. (2000). The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. *Bull Exp Biol Med Oct*; 130(10):986-90.
18. Melhem MF, Craven PA, Derubertis FR. (2001). Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes

- mellitus. *J Am Soc Nephrol* Jan; 12(1):124-133.
19. Tankova T, Koev D, Dakovska L (2004). Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). *Rom J Intern Med*; 42(2):457-64.
 20. Hahm JR, Kim BJ, Kim KW(2004). Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. *J Diabetes Complications* Mar-Apr; 18(2):79-85.
 21. Liu, F., Zhang, Y., Yang, M., Liu, B., Shen, Y. D., Jia, W. P., & Xiang, K. S. (2007). *Zhonghua yi xue za zhi*, 87(38), 2706–2709.
 22. *Yi Xue Za Zhi* (2007) Oct 16; 87(38):2706-9 [Article in Chinese].
 23. Xiang GD, Sun HL, Zhao LS, Hou J, Yue L, Xu L. (2008) The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance. *Clin Endocrinol (Oxf)* May; 68(5):716-23.
 24. Han T, Bai J, Liu W, Hu Y. (2012). A systematic review and meta-analysis of α -lipoic acid in the treatment of diabetic peripheral neuropathy. *Eur J Endocrinol* Oct; 167(4):465-71.
 25. Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G. (2022). Evaluation of the analgesic effect of α -lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res* Mar; 177:106075